U.S., Jan. 29 -- ClinicalTrials.gov registry received information related to the study (NCT06795893) titled 'The Anifrolumab PRIM Program' on Jan. 22.
Brief Summary: Pregnancy and infant outcomes in anifrolumab exposed pregnancies using PRegnancy outcomes Intensive Monitoring (PRIM) data: The anifrolumab PRIM program
Study Start Date: Feb. 28
Study Type: OBSERVATIONAL
Condition:
Systemic Lupus Erythematosus
Intervention:
DRUG: Anifrolumab
Anifrolumab is a human monoclonal antibody that binds to subunit 1 of the type 1 interferon receptor,which was developed based on the evidence supporting the role of type 1 interferon pathway in SLE. Clinical trial evidence from TULIP 1 and TULIP 2 have showed that monthly intravenous administratio...